Evidence map›Paper›PMID 36983075›Full record

ArticleInternational journal of molecular sciences2023

Mitochondrial Metabolism and EV Cargo of Endothelial Cells Is Affected in Presence of EVs Derived from MSCs on Which HIF Is Activated.

Federica Zanotti, Ilaria Zanolla, Martina Trentini, Elena Tiengo, Tommaso Pusceddu, Danilo Licastro, Margherita Degasperi, Sara Leo, Elena Tremoli, Letizia Ferroni and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Molecular Research on Heart Protection.International journal of molecular sciences · 2023
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Federica ZanottiTranslational Medicine Department, University of Ferrara, 44121 Ferrara, Italy.
Ilaria ZanollaBiomedicine Department, University of Ferrara, 44123 Ferrara, Italy.
Martina TrentiniTranslational Medicine Department, University of Ferrara, 44121 Ferrara, Italy.
Elena TiengoTranslational Medicine Department, University of Ferrara, 44121 Ferrara, Italy.
Tommaso PuscedduTranslational Medicine Department, University of Ferrara, 44121 Ferrara, Italy.
Danilo LicastroAREA Science Park, Padriciano 99, 34149 Trieste, Italy.
Margherita DegasperiAREA Science Park, Padriciano 99, 34149 Trieste, Italy.
Sara LeoGVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy.
Elena TremoliGVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy.
Letizia FerroniGVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy.
Barbara ZavanTranslational Medicine Department, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-4779-4456
University of Ferrara · ITMaria Cecilia Hospital · ITAREA Science Park · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small extracellular vesicles (sEVs) derived from mesenchymal stem cells (MSCs) have attracted growing interest as a possible novel therapeutic agent for the management of different cardiovascular diseases (CVDs). Hypoxia significantly enhances the secretion of angiogenic mediators from MSCs as well as sEVs. The iron-chelating deferoxamine mesylate (DFO) is a stabilizer of hypoxia-inducible factor 1 and consequently used as a substitute for environmental hypoxia. The improved regenerative potential of DFO-treated MSCs has been attributed to the increased release of angiogenic factors, but whether this effect is also mediated by the secreted sEVs has not yet been investigated. In this study, we treated adipose-derived stem cells (ASCs) with a nontoxic dose of DFO to harvest sEVs (DFO-sEVs). Human umbilical vein endothelial cells (HUVECs) treated with DFO-sEVs underwent mRNA sequencing and miRNA profiling of sEV cargo (HUVEC-sEVs). The transcriptomes revealed the upregulation of mitochondrial genes linked to oxidative phosphorylation. Functional enrichment analysis on miRNAs of HUVEC-sEVs showed a connection with the signaling pathways of cell proliferation and angiogenesis. In conclusion, mesenchymal cells treated with DFO release sEVs that induce in the recipient endothelial cells molecular pathways and biological processes strongly linked to proliferation and angiogenesis.

Indexed as

Extracellular VesiclesMesenchymal Stem CellsCells, CulturedDeferoxamineHumansHuman Umbilical Vein Endothelial CellsIron Chelating AgentsDeferoxamineIron Chelating Agentsdeferoxamine mesylateendothelial cellsmesenchymal stem cellsmiRNAtranscriptome

Identifiers

PMID36983075
PMCPMC10055915
OpenAlexW4353066270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.